rostafuroxin

Small moleculeexperimental

Rostafuroxin is a digitoxigenin analog that has been shown to lower blood pressure in an animal model of hypertension. It modulates the effects of the enzyme Na+/K+-ATPase, which maintains sodium and potassium ion gradients across plasma membranes. Rostafuroxin is being studied in clinical trials for the treatment of essential hypertension. — Wikipedia

Clinical trial activity

3 trials · 26 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Feb 1, 2005 (NCT00415038)

Timeline

2000s

Jan 1, 2005
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Sodium/potassium-transporting ATPase alpha-1 chainANTAGONIST
ATP1A1 antagonist
- Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) ↗

Chemistry & pharmacology

Loading structure…

SMILES

C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(c3ccoc3)CC[C@]12O

Mol. weight: 374.52 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

Also known as

17-(3-furyl)-5beta-androstane-3,14,17-triol
pst 2238
pst-2238
rostafuroxin
rostafuroxin
rostafuroxin
rostafuroxin
rostafuroxin

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03217825	Phase 2	Dec 31, 2015	CVie Therapeutics Co. Ltd.
NCT01320397	Phase 2	May 1, 2011	Katholieke Universiteit Leuven, RostaQuo S.p.A.
NCT00415038	Phase 2	Feb 1, 2005	Ballinasloe co Galway (Ireland), Centro de la Salud de Vistalegre - La Flota, Murcia (Spain), Centro de Salud Murcias San Andres - Murcia (Spain), Charles University, Hospital de Conxo - Santiago de Compostela, Hospital de Sagunto, Jagiellonian University, Katholieke Universiteit Leuven, Leadiant Biosciences, Inc., Maastricht University, Masaryk University, Medical University of Gdansk, Postgraduate Medical School, Warszawa, Poznan University, Russian Academy of Medical Sciences, Smolensk State Medical Academy, University of Barcelona, University of Brescia, University of Lausanne, University of Ljubljana, University of Santiago, University of Valencia, U.O. Cardiologia - Ospedale Civile di Schio (Vicenza) Italy, Vita-Salute University of Milano. Italy

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (26)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Katholieke Universiteit Leuven	Academic/Hospital	2	0	1	2005
Ballinasloe co Galway (Ireland)	Academic/Hospital	1	0	1	2005
Centro de la Salud de Vistalegre - La Flota, Murcia (Spain)	Academic/Hospital	1	0	1	2005
Centro de Salud Murcias San Andres - Murcia (Spain)	Academic/Hospital	1	0	1	2005
Charles University	Academic/Hospital	1	0	1	2005
CVie Therapeutics Co. Ltd.	For profit	1	1	1	2015
Hospital de Conxo - Santiago de Compostela	Academic/Hospital	1	0	1	2005
Hospital de Sagunto	Academic/Hospital	1	0	1	2005
Jagiellonian University	Academic/Hospital	1	0	1	2005
Leadiant Biosciences, Inc.	For profit	1	1	1	2005
Maastricht University	Academic/Hospital	1	0	1	2005
Masaryk University	Academic/Hospital	1	0	1	2005
Medical University of Gdansk	Academic/Hospital	1	0	1	2005
Postgraduate Medical School, Warszawa	Academic/Hospital	1	0	1	2005
Poznan University	Academic/Hospital	1	0	1	2005
RostaQuo S.p.A.	For profit	1	1	1	2011
Russian Academy of Medical Sciences	Academic/Hospital	1	0	1	2005
Smolensk State Medical Academy	Academic/Hospital	1	0	1	2005
University of Barcelona	Academic/Hospital	1	0	1	2005
University of Brescia	Academic/Hospital	1	0	1	2005

26 organizations

Page 1 / 2